Vered Stearns

Vered Stearns

Johns Hopkins University School Of Medicine, Baltimore, Md, Usa Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Md, Usa

Direct Impact

Concepts for which Vered Stearns has direct influence:

breast cancer
weight loss
hormone therapy
newly diagnosed
johns hopkins
liposomal doxorubicin
molecular profiling

External impact

Concepts related to the work of other authors for which Vered Stearns has influence:

oral oncolytic therapy
oncology practices
thirteen symptoms
paradigm shift
value-based reimbursement
revised edmonton symptom
implementing tool

Prominent publications by Vered Stearns

KOL-Index: 10 PurposePRO-cision medicine refers to personalizing care using patient-reported outcomes (PROs). We developed and feasibility-tested a PRO-cision Medicine remote PRO monitoring intervention designed to identify symptoms and reduce the frequency of routine in-person visits.MethodsWe conducted focus groups and one-on-one interviews with metastatic breast (n = 15) and prostate (n = 15) cancer ...
Known for
Alert Person | Frequently Clinicians | Intervention Metastatic | Feasibility Tested
KOL-Index: 2 RATIONALE: Studying samples of blood and pleural or peritoneal fluid from patients with metastatic breast cancer in the laboratory may help doctors identify biomarkers related to breast cancer and learn more about how breast cancer begins and spreads in the body.PURPOSE: This research study is looking at a new way of identifying circulating breast cancer cells in blood and in pleural or ...
Known for
Clonogenic Growth | Highly Enrich | Density Centrifugation | Epithelial Origin
KOL-Index: 2 This study will test the feasibility of identifying patients who could benefit from tumor molecular profiling, of analyzing the patients' tumors in a timely (28 day) fashion, and of the identification of possible actionable mutations that are not just biologically interesting but are clinically relevant. The investigators will also examine the outcome data from patients who followed the ...
Known for
Correct Choice | Actionable Mutations | Technical Issues
KOL-Index: 2 This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 weeks. Detailed Description Key eligibility criteria include:Newly ...
Known for
Combination Vorinostat | Therapy Prior | Cancer Tissue | Designed Effects
KOL-Index: 2 The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue. Detailed Description Breast cancer cells grow in a low oxygen environment called hypoxia. The body normally controls the amount of oxygen in cells with what is known as Hypoxia-inducible factor (HIF)-1. HIF-1 helps cancer cells grow in low oxygen environments; therefore, if this function ...
Known for
Digoxin Learn | Oxygen Environment | Detailed Breast | Tissue Comparing
KOL-Index: 2 RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may also help carboplatin and paclitaxel ...
Known for
Repeats Weekly | Oral Vorinostat | Toxicity Arm | Pet Pathological
KOL-Index: 2 RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells.PURPOSE: This phase II trial is studying how well tamoxifen citrate works in patients with metastatic or recurrent breast cancer. Detailed Description OBJECTIVES:PrimaryTo correlate CYP2D6 score (0 vs 1-2) and ...
Known for
Pfs Months | Response Treated | Estrogen Growth | Cyp2d6 Free
KOL-Index: 2 RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole may fight breast cancer by lowering the amount of estrogen the body makes.PURPOSE: This phase II trial is studying how anastrozole effects postmenopausal women who have undergone surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer. Detailed Description ...
Known for
Lowering Estrogen | Women Dcis | Treated Adjuvant | Ductal Carcinoma
KOL-Index: 2 The purpose of this project is to establish a repository of information and samples from breast cancer patients or those at high risk of developing breast cancer, who are initiating hormone therapy as part of standard clinical care or prevention. This repository will include patient reported outcomes and other questionnaires, information on medication use, data about adherence to the hormone ...
Known for
Hormone Therapies
KOL-Index: 2 RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of simvastatin may keep cancer from coming back in women who are at high risk for a new breast cancer after undergoing surgery for ductal carcinoma in situ or stage I, stage II, or stage III breast cancer.PURPOSE: This phase II trial is studying how well simvastatin works in ...
Known for
Estrogen Concentrations | Cumulative Methylation

Johns Hopkins University School of Medicine, Baltimore, MD, USA Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172